Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Yahoo! Finance
US$0.37 loss per share (improved from US$0.74 loss in FY 2023). NasdaqGS:OVID Earnings and Revenue History March 12th 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Ovid Therapeutics EPS Beats Expectations, Revenues Fall Short Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 21%. Looking ahead, revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 3.9% from a week ago. Risk Analysis It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Ovid Therapeutics (at least 3 which are concerning) , and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, ema
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.MarketBeat
- Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical OfficerGlobeNewswire
- Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
OVID
Earnings
- 11/12/25 - Miss
OVID
Sec Filings
- 12/15/25 - Form S-3
- 12/11/25 - Form 8-K
- 12/9/25 - Form 4
- OVID's page on the SEC website